N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 1 / Phase 2 ClinicalTrials.gov

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Sponsor: Boehringer Ingelheim • ClinicalTrials.gov ID: NCT06324357

Registry updated: 2026-10-14
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not successful. The purpose of this study is to find a suitable dose of zongertinib that people with different types of HER2+ cancer that has spread can tolerate best when taken together with trastuzumab deruxtecan (T-DXd), with trastuzumab emtansine (T-DM1), with trastuzumab and capecitabine, with zanidatamab, or with mFOLFOX6 (with or without trastuzumab). Another purpose is to check whether zongertinib alone and in combination with other treatments can make tumours shrink. Zongertinib inhibits HER2. HER2 causes cancer cells to grow. In this study, participants receive treatment in cycles. Study participants are treated with zongertinib alone or in combination with other treatments. This study has 2 parts. In Part 1, participants in different groups receive increasing doses of zongertinib. In Part 2, participants are put into different groups by chance. Each group receives a different dose of zongertinib. Every participant has an equal chance of being in each group. During the study, the participants visit the study site regularly. In this study, researchers want to find the highest dose of zongertinib that participants can tolerate when taken together with other treatments. To find this out, researchers look at certain severe health problems that a number of participants have. The doctors regularly check the size of the tumour with imaging methods (CT/MRI) during the study. The doctors also regularly check participants' health and take note of any unwanted effects.

Interventions

  • Zongertinib (Drug)
    Zongertinib
  • Trastuzumab deruxtecan (Drug)
    Trastuzumab deruxtecan
  • Trastuzumab emtansine (Drug)
    Trastuzumab emtansine
  • Trastuzumab (Drug)
    Herceptin®
  • Capecitabine (Drug)
    Xeloda®
  • mFOLFOX6 (Drug)
    mFOLFOX6
  • zanidatamab (Drug)
    zanidatamab

Eligibility criteria

Inclusion criteria: * Patients ≥18 years of age or over the legal age of consent in countries where that is greater than 18 years at the time of signature of the informed consent form (ICF) * Cohorts A to K and Cohort O: Documented Human epidermal growth factor receptor 2 overexpressing and/or amplified (HER2+), metastatic breast cancer (mBC) or metastatic gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma (mGEAC). * Cohorts L (L-ext), M, and N (metastatic colorectal cancer (mCRC)): Documented Human epidermal growth factor receptor 2 (HER2) overexpression/amplification according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) gastric cancer guidelines and according to the result of local testing. * For dose optimization and justification (Phase II): Patient must provide tumor tissue from locations not radiated prior to biopsy, if possible, collected through archival tissue * History of prior treatment lines in palliative setting: * For cohorts A, B, C, D, E, F, G, H, I, I-ext, J, J-ext, K and O documented investigator assessed progression after HER2-directed treatment for unresectable locally advanced or metastatic disease (For Cohorts D, H, I (I-ext), J (J-ext) - patients must have been pretreated with trastuzumab deruxtecan (T-DXd) and have progressed or have been intolerant to previous T-DXd). * For cohorts L, L-ext, M and N documented progression or recurrence of disease during or following their latest line of therapy. Patients must have had at least one prior line of therapy for locally advanced unresectable disease or metastatic disease (adjuvant and neoadjuvant therapy excluded) and documented disease progression or recurrence of disease during or following their latest line of therapy. In the opinion of the Investigator, patients must be unlikely to tolerate or derive clinically meaningful benefit from further standard of care therapy known to prolong survival. * Presence of at least one measurable lesion according to RECIST 1.1 * Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 * Adequate organ function based on laboratory values Further inclusion criteria apply. Exclusion criteria: * Previous treatment with: * Any small molecule HER2 inhibitor in the palliative setting in Cohorts D, E, F, H, L, L-ext, M, and N. In Cohort D allowed in up to 15 patients in each dose level (DL). * T-DXd in Cohorts E and F. In Cohort E allowed in up to 15 patients in each DL. * trastuzumab emtansine (T-DM1) in the palliative setting in Cohort D and H. In Cohort H allowed in up to 15 patients in each DL. * Capecitabine in Cohort D and H. In Cohort D allowed in up to 15 patients in each DL * Presence of uncontrolled and/or symptomatic brain metastases, or leptomeningeal disease * Mean resting corrected QT interval (QT interval corrected for heart rate by Fridericia´s formula (QTcF)) \>470 msec. * Any factors that increase the risk of QT interval corrected for heart rate (QTc) prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, personal or family history of long QT syndrome or unexplained sudden death under 40 years-of-age. * Ejection fraction \<50% or the lower limit of normal of the institutional standard within 28 days prior to randomization * History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening Further exclusion criteria apply.

Conditions

Metastatic Breast Cancer Metastatic Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Esophageal Adenocarcinoma Colorectal Cancer

Locations

  • The Oncology Institute of Hope and Innovation — Cerritos, California, United States
  • Ellison Medical Institute — Los Angeles, California, United States
  • Valkyrie Clinical Trials — Los Angeles, California, United States
  • University of California Los Angeles — Los Angeles, California, United States
  • University of California Irvine — Orange, California, United States
  • Sharp Memorial Hospital — San Diego, California, United States
  • Yale University School of Medicine — New Haven, Connecticut, United States
  • Helios CR Inc — Lakeland, Florida, United States
  • H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
  • Orchard Healthcare Research Inc.- Skokie — Skokie, Illinois, United States
  • Community Health Network — Indianapolis, Indiana, United States
  • University of Iowa Hospitals and Clinics — Iowa City, Iowa, United States
  • Dana-Farber Cancer Institute — Boston, Massachusetts, United States
  • University of Michigan — Ann Arbor, Michigan, United States
  • Memorial Sloan-Kettering Cancer Center — New York, New York, United States
  • New York Cancer & Blood Specialists — Shirley, New York, United States
  • Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania, United States
  • Avera Cancer Institute — Sioux Falls, South Dakota, United States
  • Baptist Cancer Center - Memphis — Memphis, Tennessee, United States
  • SCRI Oncology Partners — Nashville, Tennessee, United States
  • Tennessee Oncology, Pllc — Nashville, Tennessee, United States
  • The Methodist Hospital Research Institute — Houston, Texas, United States
  • The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
  • Inova Schar Cancer Institute — Fairfax, Virginia, United States
  • Virginia Cancer Specialists, PC — Fairfax, Virginia, United States
  • Fred Hutchinson Cancer Research Center — Seattle, Washington, United States
  • Cliniques Universitaires Saint-Luc — Brussels, Belgium
  • Universitair Ziekenhuis Antwerpen — Edegem, Belgium
  • UZ Leuven — Leuven, Belgium
  • Hôpital Vivalia De Libramont — Libramont-Chevigny, Belgium
  • Centre Hospitalier Universitaire de Liège — Liège, Belgium
  • CHU UCL Namur — Namur, Belgium
  • Jilin Province Cancer Hospital — Changchun, China
  • The First Hospital of Jilin University — Changchun, China
  • Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine — Hangzhou, China
  • Harbin Medical University Cancer Hospital — Harbin, China
  • Jiangsu Province Hospital — Nanjing, China
  • Fudan University Shanghai Cancer Center — Shanghai, China
  • Tianjin Cancer Hospital — Tianjin, China
  • Henan Cancer Hospital — Zhengzhou, China
  • INS Bergonie — Bordeaux, France
  • CTR François Baclesse — Caen, France
  • CTR Leon Berard — Lyon, France
  • INS Paoli-Calmettes — Marseille, France
  • HOP Tenon — Paris, France
  • CTR Eugène Marquis — Rennes, France
  • Institut de Cancérologie de l'Ouest — Saint-Herblain, France
  • Institut de Cancérologie de Strasbourg — Strasbourg, France
  • INS Claudius Regaud IUCT-Oncopole — Toulouse, France
  • Institut Gustave Roussy — Villejuif, France
  • Universitätsklinikum Carl Gustav Carus Dresden — Dresden, Germany
  • Universitätsklinikum Erlangen — Erlangen, Germany
  • Evang. Kliniken Essen-Mitte gGmbh — Essen, Germany
  • Asklepios Kliniken GmbH & Co. KGaA — Hamburg, Germany
  • Universitätsklinikum Mannheim GmbH — Mannheim, Germany
  • Universitätsklinikum Ulm — Ulm, Germany
  • Azienda Ospedaliero Universitaria delle Marche — Ancona, Italy
  • Istituto Di Candiolo — Candiolo (TO), Italy
  • Istituto Scientifico Romagnolo — Meldola (FC), Italy
  • Ospedale San Raffaele S.r.l. — Milan, Italy
  • Istituto Europeo di Oncologia — Milan, Italy
  • Humanitas Istituto Clinico Catanese S.p.A. — Misterbianco (CT), Italy
  • Istituto Nazionale IRCCS Tumori Fondazione Pascale — Naples, Italy
  • Istituto Clinico Humanitas — Rozzano, Italy
  • Aichi Cancer Center Hospital — Aichi, Nagoya, Japan
  • Tokai University Hospital — Isehara, Japan
  • Hakuaikai Sagara Hospital — Kagoshima, Japan
  • Kanagawa Cancer Center — Kanagawa, Yokohama, Japan
  • National Cancer Center Hospital East — Kashiwa-shi, Japan
  • Kyoto University Hospital — Kyoto, Japan
  • Osaka International Cancer Institute — Osaka, Japan
  • Japanese Foundation for Cancer Research — Tokyo, Koto-ku, Japan
  • CHA Bundang Medical Center — Seongnam-si, South Korea
  • Seoul National University Bundang Hospital — Seongnam-si, South Korea
  • Seoul National University Hospital — Seoul, South Korea
  • Severance Hospital, Yonsei University Health System — Seoul, South Korea
  • Asan Medical Center — Seoul, South Korea
  • Korea University Anam Hospital — Seoul, South Korea
  • The Catholic University of Korea, Seoul St.Mary's Hospital — Seoul, South Korea
  • Severance Hospital, Yonsei University Health System — Seoul, South Korea
  • Complejo Hospitalario Universitario A Coruña — A Coruña, Spain
  • Hospital del Mar — Barcelona, Spain
  • Hospital Universitari Vall d'Hebron — Barcelona, Spain
  • Hospital Clínic de Barcelona — Barcelona, Spain
  • Hospital Duran i Reynals — L'Hospitalet de Llobregat, Spain
  • Hospital General Universitario Gregorio Marañón — Madrid, Spain
  • Clínica Universidad de Navarra - Madrid — Madrid, Spain
  • Fundación Jiménez Díaz — Madrid, Spain
  • Hospital Clínico San Carlos — Madrid, Spain
  • Hospital Universitario 12 de Octubre — Madrid, Spain
  • Hospital Universitario La Paz — Madrid, Spain
  • CIO Clara Campal — Madrid, Spain
  • Hospital Universitario Virgen De La Macarena — Seville, Spain
  • Instituto Valenciano de Oncología — Valencia, Spain
  • Velindre Cancer Centre — Cardiff, United Kingdom
  • St James's University Hospital — Leeds, United Kingdom
  • St Bartholomew's Hospital — London, United Kingdom
  • University College Hospital — London, United Kingdom
  • Royal Free Hospital — London, United Kingdom
  • The Royal Marsden Hospital, Chelsea — London, United Kingdom
  • The Christie Hospital — Manchester, United Kingdom
  • Freeman Hospital — Newcastle upon Tyne, United Kingdom
  • Nottingham University Hospital — Nottingham, United Kingdom
  • The Royal Marsden Hospital, Sutton — Sutton, United Kingdom
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record